| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $95M | ||
| $91M |
Buys | $ | – | |
Sells | $ | – |
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
Over the last 12 months, insiders at Kezar Life Sciences, Inc. have bought $undefined and sold $undefined worth of Kezar Life Sciences, Inc. stock.
On average, over the past 5 years, insiders at Kezar Life Sciences, Inc. have bought $295,400 and sold $980,348 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $295,400 was made by BERGER FRANKLIN M () on 2022‑03‑18.
| Increased Positions | 21 | +42% | 981,670 | +23.34% |
| Decreased Positions | 22 | -44% | 644,358 | -15.32% |
| New Positions | 11 | New | 868,905 | New |
| Sold Out Positions | 5 | Sold Out | 278,275 | Sold Out |
| Total Postitions | 49 | -2% | 5M | +8.02% |
| Bml Capital Management, Llc | $4,534.00 | 10.3% | 720,787 | +85,604 | +13.48% | 2025-09-30 |
| Tang Capital Management Llc | $4,529.00 | 10.29% | 720,000 | 0 | 0% | 2025-09-30 |
| Suvretta Capital Management, Llc | $4,508.00 | 10.24% | 716,759 | 0 | 0% | 2025-09-30 |
| Stonepine Capital Management, Llc | $2,410.00 | 5.47% | 383,182 | +213,323 | +125.59% | 2025-09-30 |
| Vanguard Group Inc | $1,687.00 | 3.83% | 268,166 | -8,062 | -2.92% | 2025-09-30 |
| Orbimed Advisors Llc | $1,212.00 | 2.75% | 192,700 | 0 | 0% | 2025-09-30 |
| Acadian Asset Management Llc | $840.00 | 1.91% | 133,525 | 0 | 0% | 2025-09-30 |
| Peapod Lane Capital Llc | $791.00 | 1.8% | 125,773 | +10,650 | +9.25% | 2025-09-30 |
| Adar1 Capital Management, Llc | $786.00 | 1.79% | 124,967 | -22,437 | -15.22% | 2025-09-30 |
| Renaissance Technologies Llc | $729.00 | 1.66% | 115,885 | +28,601 | +32.77% | 2025-09-30 |